Employees Also Raised More Than $55,000 at Third Annual "One Astellas Spirit Run" for Seven Charitable Organizations

-Updated Data from Phase 1 EV-101 Study Highlighted in ASCO 2018 Oral Presentation Support Rapid Development Program and Ongoing Pivotal Study-

2018 Challenge Will Award a Total of $100,000 in New Grants to Help Reduce the Unequal Burden of Cancer

Joins Company's Executive Leadership Team

Asset Transfer was Completed on April 12, 2018

Dragovic was previously Vice President, Ethics & Compliance Americas

sNDA Seeks to Expand the Indication of XTANDI to include Men with Non-metastatic CRPC

Barretto-Ko was previously Senior Vice President, International Operations

Acquisition enables Astellas to fully utilize proprietary technology to produce pluripotent stem cells that have the potential to lower immunological rejection in numerous therapeutic areas

- A total of 10 abstracts and one trial in progress (TIP) across various cancers to be presented during oral and poster sessions -

- Gilteritinib combined with intensive chemotherapy was well-tolerated in newly diagnosed AML patients -

- Accelerating the Discovery and Development of Novel Drugs that Target Mitochondrial Functions -

- A breadth of abstracts highlighting the acute myeloid leukemia treatment landscape, healthcare resource use and cost of care to be presented during oral and poster sessions -

- Grand Prize winner Hernâni Oliveira of Porto, Portugal will receive a $50,000 grant from Astellas plus a one-year nights and weekends membership to MATTER, a healthcare innovation community -

ADC Combination Study Focuses on First-Line Treatment

James Miteff and Gregory Apostol promoted to key national leadership roles.

In the challenge's second year, five entrants will compete for a chance to win a Grand Prize of $50,000 from Astellas and a consultation with Robert Herjavec, star of ABC's Emmy Award-winning hit television show, Shark Tank

Solid Tumor Antibody-Drug Conjugate (ADC) Enfortumab Vedotin to be Evaluated as a Monotherapy in Patients Previously Treated with a Checkpoint Inhibitor

Astellas ranked in recognition of its commitment and support for working mothers

- Enzalutamide is the first androgen receptor-inhibitor to demonstrate a statistically significant improvement in metastasis-free survival (MFS) in this patient population in a randomized, controlled clinical trial

If approved, the combination therapy could potentially offer a new treatment option for patients whose overactive bladder symptoms are not adequately controlled on monotherapy

Winner will attend live taping of ABC's "Dancing with the Stars"